Buy JNJ ahead of next year’s spinoff

Article Excerpt

Pharmaceutical giant Johnson & Johnson still plans to spin off its consumer operations in 2023 as a new firm called Kenvue. Even though Kenvue’s products are less profitable than prescription drugs and medical devices, it owns some of the world’s best-known brands and generates steady cash flows. That cuts its risk, and should let it reward investors with higher dividends. JOHNSON & JOHNSON $165 is a spinoff buy. The company (New York symbol JNJ; Consumer sector; Shares outstanding: 2.6 billion; Market cap: $429.0 billion; Dividend yield: 2.7%; Takeover Target Rating: Medium; www.jnj.com) is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. Johnson & Johnson now plans to spin off its Consumer Health business from the rest of the company. It plans to carry out the separation in 2023. Revenue at the new Consumer Health business (called Kenvue) totalled $14.6 billion in 2021. That includes four megabrands with annual sales of $1 billion each, and 20 brands with annual sales over $150 million each. About…